Literature DB >> 3942736

Cyclosporin A and a diaziridine derivative inhibit the hepatocellular uptake of cholate, phalloidin and rifampicin.

K Ziegler, M Frimmer.   

Abstract

Cyclosporin A inhibits the uptake of cholate into isolated hepatocytes in a non-competitive manner (Ki = 3.6 microM). It protects liver cells against phalloidin injury by a mixed competitive/non-competitive inhibition of phalloidin uptake (Ki = 0.08 microM). Rifampicin, a well-known substrate of the bilirubin transporter is also incorporated in a decreased quantity in the presence of cyclosporin A (IC50 = 80 microM). A photolabile diaziridine derivative of cyclosporin A was used for the identification of binding sites. In comparison with the original cyclosporin A the photoaffinity label exhibits a 2-3-fold lower affinity to the cholate (and phalloidin) transporter in the liver cell membrane. In the dark the label inhibits the uptake of both cholate and of phalloidin reversibly; after treatment with ultraviolet light flashes the inhibition becomes irreversible. The degree of inhibition is concentration dependent. Our results suggest binding of cyclosporin A to protein components of the cholate (and phalloidin) transporter of liver cells without uptake by this system. The inhibition of cholate (and phalloidin) uptake by cyclosporin A is non-competitive and may be due to nonspecific hydrophobic binding to compounds of the cholate transporter.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3942736     DOI: 10.1016/0005-2736(86)90197-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

2.  Uptake, production and metabolism of cysteinyl leukotrienes in the isolated perfused rat liver. Inhibition of leukotriene uptake by cyclosporine.

Authors:  W Hagmann; S Parthé; I Kaiser
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

3.  The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae.

Authors:  J Heitman; A Koller; J Kunz; R Henriquez; A Schmidt; N R Movva; M N Hall
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

4.  Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat.

Authors:  P E Queneau; P Bertault-Peres; M Guitaoui; E Mesdjian; A Durand; J C Montet
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

5.  Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man.

Authors:  J F Cadranel; S Erlinger; M Desruenne; J Luciani; F Lunel; P Grippon; A Cabrol; P Opolon
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

6.  Effect of chronic administration of cyclosporin A on hepatic uptake and biliary secretion of bromosulfophthalein in rat.

Authors:  J F Cadranel; M Dumont; V A Mesa; C Degott; D Touchard; S Erlinger
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

7.  Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestatic action?

Authors:  G Fricker; A Fahr
Journal:  Yale J Biol Med       Date:  1997 Jul-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.